Bruker (BRKR) PT Lowered to $31.00 at Morgan Stanley

Bruker (NASDAQ:BRKR) had its price objective decreased by Morgan Stanley from $32.00 to $31.00 in a research report sent to investors on Wednesday. Morgan Stanley currently has an equal weight rating on the medical research company’s stock.

Other analysts have also recently issued research reports about the company. Leerink Swann raised their price target on Bruker from $32.00 to $34.00 and gave the company a market perform rating in a report on Friday, February 9th. Evercore ISI initiated coverage on Bruker in a report on Wednesday, January 3rd. They issued an in-line rating and a $36.00 price target on the stock. BidaskClub cut Bruker from a buy rating to a hold rating in a report on Saturday, February 10th. Zacks Investment Research cut Bruker from a strong-buy rating to a hold rating in a report on Wednesday, January 3rd. Finally, BTIG Research initiated coverage on Bruker in a report on Friday, January 5th. They issued a buy rating and a $42.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have assigned a buy rating to the stock. Bruker currently has a consensus rating of Hold and a consensus target price of $32.54.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ BRKR opened at $30.17 on Wednesday. Bruker has a 52 week low of $21.83 and a 52 week high of $36.53. The company has a quick ratio of 1.66, a current ratio of 2.59 and a debt-to-equity ratio of 0.57. The stock has a market capitalization of $4,673.96, a price-to-earnings ratio of 24.93, a P/E/G ratio of 1.99 and a beta of 1.12.

Bruker (NASDAQ:BRKR) last issued its earnings results on Thursday, February 8th. The medical research company reported $0.51 EPS for the quarter, topping the consensus estimate of $0.49 by $0.02. Bruker had a return on equity of 26.68% and a net margin of 4.45%. The business had revenue of $530.50 million during the quarter, compared to the consensus estimate of $506.74 million. During the same quarter last year, the company earned $0.46 EPS. The firm’s revenue was up 12.8% compared to the same quarter last year. equities analysts forecast that Bruker will post 1.37 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 23rd. Investors of record on Tuesday, March 6th were issued a dividend of $0.04 per share. The ex-dividend date was Monday, March 5th. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.53%. Bruker’s dividend payout ratio is 13.22%.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Acadian Asset Management LLC raised its holdings in shares of Bruker by 5.7% during the 4th quarter. Acadian Asset Management LLC now owns 5,229,258 shares of the medical research company’s stock valued at $179,467,000 after buying an additional 280,245 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Bruker by 7.1% during the 4th quarter. BlackRock Inc. now owns 5,173,860 shares of the medical research company’s stock valued at $177,566,000 after buying an additional 341,389 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Bruker by 2.5% during the 4th quarter. Geode Capital Management LLC now owns 1,294,131 shares of the medical research company’s stock valued at $44,414,000 after buying an additional 31,742 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Bruker by 1.3% during the 3rd quarter. Dimensional Fund Advisors LP now owns 921,431 shares of the medical research company’s stock valued at $27,412,000 after buying an additional 11,466 shares in the last quarter. Finally, Wells Fargo & Company MN raised its holdings in shares of Bruker by 4.7% during the 3rd quarter. Wells Fargo & Company MN now owns 845,373 shares of the medical research company’s stock valued at $25,150,000 after buying an additional 37,858 shares in the last quarter. 65.27% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Bruker (BRKR) PT Lowered to $31.00 at Morgan Stanley” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/15/bruker-brkr-pt-lowered-to-31-00-at-morgan-stanley.html.

About Bruker

Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions worldwide. The company operates through two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear and explosive detection in emergency response, homeland security, and defense applications; and analytical and process analysis instruments and solutions.

Analyst Recommendations for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply